BIOCRYST PHARMACEUTICALS, INC. Research and Development Expense
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Research and Development Expense of $51.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $51.97M, a 19.78% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $60.32M, a 61.84% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $40.87M, a 17.34% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $44.60M, a 8.57% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $166.13M, a 4.87% decline from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $174.64M, a 19.36% decline from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $216.57M, a 14.50% decline from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $253.30M, a 21.31% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $51.97M 10-Q · filed 2026-08-05 | $112.29M 10-Q · filed 2026-08-05 | $153.16M derived: sum of 3 quarters · filed 2026-08-05 | $197.76M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $60.32M 10-Q · filed 2026-05-06 | $101.19M derived: sum of 2 quarters · filed 2026-05-06 | $145.79M derived: sum of 3 quarters · filed 2026-05-06 | $189.18M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $40.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $85.47M derived: sum of 2 quarters · filed 2026-02-26 | $128.86M derived: sum of 3 quarters · filed 2026-08-05 | $166.13M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $44.60M 10-Q · filed 2025-11-04 | $87.99M derived: sum of 2 quarters · filed 2026-08-05 | $125.26M 10-Q · filed 2025-11-04 | $174.70M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $43.39M 10-Q · filed 2026-08-05 | $80.66M 10-Q · filed 2026-08-05 | $130.10M derived: sum of 3 quarters · filed 2026-08-05 | $171.18M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $37.27M 10-Q · filed 2026-05-06 | $86.71M derived: sum of 2 quarters · filed 2026-05-06 | $127.79M derived: sum of 3 quarters · filed 2026-05-06 | $165.41M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $49.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $90.52M derived: sum of 2 quarters · filed 2026-02-26 | $128.15M derived: sum of 3 quarters · filed 2026-02-26 | $174.64M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $41.08M 10-Q · filed 2025-11-04 | $78.70M derived: sum of 2 quarters · filed 2025-11-04 | $125.20M 10-Q · filed 2025-11-04 | $195.25M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $37.62M 10-Q · filed 2025-08-05 | $84.12M 10-Q · filed 2025-08-05 | $154.17M derived: sum of 3 quarters · filed 2026-02-26 | $201.05M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $46.49M 10-Q · filed 2025-05-06 | $116.55M derived: sum of 2 quarters · filed 2026-02-26 | $163.42M derived: sum of 3 quarters · filed 2026-02-26 | $214.67M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $70.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $116.93M derived: sum of 2 quarters · filed 2026-02-26 | $168.18M derived: sum of 3 quarters · filed 2026-02-26 | $216.57M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $46.88M 10-Q · filed 2024-11-05 | $98.13M derived: sum of 2 quarters · filed 2024-11-05 | $146.51M 10-Q · filed 2024-11-05 | $219.72M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $51.25M 10-Q · filed 2024-08-06 | $99.64M 10-Q · filed 2024-08-06 | $172.84M derived: sum of 3 quarters · filed 2025-02-25 | $225.58M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $48.39M 10-Q · filed 2024-05-07 | $121.59M derived: sum of 2 quarters · filed 2025-02-25 | $174.34M derived: sum of 3 quarters · filed 2025-02-25 | $236.32M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $73.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $125.95M derived: sum of 2 quarters · filed 2025-02-25 | $187.94M derived: sum of 3 quarters · filed 2025-02-25 | $253.30M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $52.74M 10-Q · filed 2023-11-08 | $114.73M derived: sum of 2 quarters · filed 2023-11-08 | $180.09M 10-Q · filed 2023-11-08 | $243.62M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $61.99M 10-Q · filed 2023-08-07 | $127.35M 10-Q · filed 2023-08-07 | $190.88M derived: sum of 3 quarters · filed 2024-02-27 | $240.85M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $65.36M 10-Q · filed 2023-05-08 | $128.89M derived: sum of 2 quarters · filed 2024-02-27 | $178.86M derived: sum of 3 quarters · filed 2024-02-27 | $231.73M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $63.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $113.50M derived: sum of 2 quarters · filed 2024-02-27 | $166.37M derived: sum of 3 quarters · filed 2024-02-27 | $208.81M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $49.97M 10-Q · filed 2022-11-04 | $102.84M derived: sum of 2 quarters · filed 2022-11-04 | $145.28M 10-Q · filed 2022-11-04 | $180.63M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $52.87M 10-Q · filed 2022-08-05 | $95.31M 10-Q · filed 2022-08-05 | $130.66M derived: sum of 3 quarters · filed 2023-02-27 | $160.91M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | $42.44M 10-Q · filed 2022-05-09 | $77.79M derived: sum of 2 quarters · filed 2023-02-27 | $108.03M derived: sum of 3 quarters · filed 2023-02-27 | $135.53M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | $35.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $65.60M derived: sum of 2 quarters · filed 2023-02-27 | $93.10M derived: sum of 3 quarters · filed 2023-02-27 | $122.96M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | $30.25M 10-Q · filed 2021-11-04 | $57.74M derived: sum of 2 quarters · filed 2021-11-04 | $87.61M 10-Q · filed 2021-11-04 | $114.38M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $27.50M 10-Q · filed 2021-08-09 | $57.37M 10-Q · filed 2021-08-09 | $84.14M derived: sum of 3 quarters · filed 2022-02-28 | $109.26M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $29.87M 10-Q · filed 2021-05-07 | $56.64M derived: sum of 2 quarters · filed 2022-02-28 | $81.76M derived: sum of 3 quarters · filed 2022-02-28 | $109.44M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $26.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $51.89M derived: sum of 2 quarters · filed 2022-02-28 | $79.58M derived: sum of 3 quarters · filed 2022-02-28 | $107.07M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $25.12M 10-Q · filed 2020-11-06 | $52.80M derived: sum of 2 quarters · filed 2020-11-06 | $80.29M 10-Q · filed 2020-11-06 | $103.72M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $27.68M 10-Q · filed 2020-08-07 | $55.17M 10-Q · filed 2020-08-07 | $78.61M derived: sum of 3 quarters · filed 2021-03-01 | $100.61M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $27.49M 10-Q · filed 2020-05-11 | $50.92M derived: sum of 2 quarters · filed 2021-03-01 | $72.93M derived: sum of 3 quarters · filed 2021-03-01 | $93.94M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $23.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $45.44M derived: sum of 2 quarters · filed 2021-03-01 | $66.45M derived: sum of 3 quarters · filed 2021-03-01 | $84.89M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $22.01M 10-Q · filed 2019-11-08 | $43.02M derived: sum of 2 quarters · filed 2019-11-08 | $61.46M 10-Q · filed 2019-11-08 | $78.38M derived: sum of 4 quarters · filed 2020-03-13 | ||||
| 2018-06-30 | $21.01M 10-Q · filed 2019-08-08 | $39.45M 10-Q · filed 2019-08-08 | $56.38M derived: sum of 3 quarters · filed 2020-03-13 | $73.88M derived: sum of 4 quarters · filed 2020-03-13 | ||||
| 2018-03-31 | $18.44M 10-Q · filed 2019-05-09 | $35.37M derived: sum of 2 quarters · filed 2020-03-13 | $52.87M derived: sum of 3 quarters · filed 2020-03-13 | $68.63M derived: sum of 4 quarters · filed 2020-03-13 | ||||
| 2017-12-31 | $16.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $34.43M derived: sum of 2 quarters · filed 2020-03-13 | $50.19M derived: sum of 3 quarters · filed 2020-03-13 | $66.96M 10-K · filed 2020-03-13 | ||||
| 2017-09-30 | $17.51M 10-Q · filed 2018-11-08 | $33.27M derived: sum of 2 quarters · filed 2018-11-08 | $50.04M 10-Q · filed 2018-11-08 | $62.20M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-06-30 | $15.76M 10-Q · filed 2018-08-09 | $32.53M 10-Q · filed 2018-08-09 | $44.69M derived: sum of 3 quarters · filed 2019-03-14 | $58.79M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-03-31 | $16.77M 10-Q · filed 2018-05-09 | $28.93M derived: sum of 2 quarters · filed 2019-03-14 | $43.03M derived: sum of 3 quarters · filed 2019-03-14 | $57.20M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2016-12-31 | $12.16M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $26.26M derived: sum of 2 quarters · filed 2019-03-14 | $40.43M derived: sum of 3 quarters · filed 2019-03-14 | $61.01M 10-K · filed 2019-03-14 | ||||
| 2016-09-30 | $14.11M 10-Q · filed 2017-11-08 | $28.27M derived: sum of 2 quarters · filed 2017-11-08 | $48.85M 10-Q · filed 2017-11-08 | $67.90M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-06-30 | $14.17M 10-Q · filed 2017-08-08 | $34.74M 10-Q · filed 2017-08-08 | $53.79M derived: sum of 3 quarters · filed 2018-03-12 | $73.86M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-03-31 | $20.58M 10-Q · filed 2017-05-08 | $39.63M derived: sum of 2 quarters · filed 2018-03-12 | $59.69M derived: sum of 3 quarters · filed 2018-03-12 | $76.22M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2015-12-31 | $19.05M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $39.11M derived: sum of 2 quarters · filed 2018-03-12 | $55.64M derived: sum of 3 quarters · filed 2018-03-12 | $72.76M 10-K · filed 2018-03-12 | ||||
| 2015-09-30 | $20.07M 10-Q · filed 2016-11-08 | $36.59M derived: sum of 2 quarters · filed 2016-11-08 | $53.71M 10-Q · filed 2016-11-08 | $72.22M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-06-30 | $16.52M 10-Q · filed 2016-08-08 | $33.64M 10-Q · filed 2016-08-08 | $52.15M derived: sum of 3 quarters · filed 2017-02-27 | $65.19M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-03-31 | $17.12M 10-Q · filed 2016-05-09 | $35.63M derived: sum of 2 quarters · filed 2017-02-27 | $48.67M derived: sum of 3 quarters · filed 2017-02-27 | $59.73M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2014-12-31 | $18.51M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $31.55M derived: sum of 2 quarters · filed 2017-02-27 | $42.61M derived: sum of 3 quarters · filed 2017-02-27 | $51.80M 10-K · filed 2017-02-27 | ||||
| 2014-09-30 | $13.04M 10-Q · filed 2015-11-06 | $24.10M derived: sum of 2 quarters · filed 2015-11-06 | $33.29M 10-Q · filed 2015-11-06 | $48.75M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-06-30 | $11.07M 10-Q · filed 2015-08-07 | $20.25M 10-Q · filed 2015-08-07 | $35.72M derived: sum of 3 quarters · filed 2016-02-26 | $43.45M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-03-31 | $9.18M 10-Q · filed 2015-05-08 | $24.65M derived: sum of 2 quarters · filed 2016-02-26 | $32.38M derived: sum of 3 quarters · filed 2016-02-26 | $43.91M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2013-12-31 | $15.47M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $23.20M derived: sum of 2 quarters · filed 2016-02-26 | $34.73M derived: sum of 3 quarters · filed 2016-02-26 | $41.94M 10-K · filed 2016-02-26 | $42.73M 10-K · filed 2014-03-10 | |||
| 2013-09-30 | $7.74M 10-Q · filed 2014-11-07 | $7.98M 10-Q · filed 2013-11-08 | $19.26M derived: sum of 2 quarters · filed 2014-11-07 | $26.48M 10-Q · filed 2014-11-07 | $27.12M 10-Q · filed 2013-11-08 | $35.26M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $11.53M 10-Q · filed 2014-08-08 | $11.73M 10-Q · filed 2013-08-08 | $18.74M 10-Q · filed 2014-08-08 | $19.14M 10-Q · filed 2013-08-08 | $27.53M derived: sum of 3 quarters · filed 2015-03-02 | $39.60M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | $7.21M 10-Q · filed 2014-05-09 | $7.41M 10-Q · filed 2013-05-09 | $16.00M derived: sum of 2 quarters · filed 2015-03-02 | $28.07M derived: sum of 3 quarters · filed 2015-03-02 | $40.85M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2012-12-31 | $8.79M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $20.86M derived: sum of 2 quarters · filed 2015-03-02 | $33.63M derived: sum of 3 quarters · filed 2015-03-02 | $49.16M 10-K · filed 2015-03-02 | $51.46M 10-K · filed 2013-03-11 | |||
| 2012-09-30 | $12.07M 10-Q · filed 2013-11-08 | $24.85M derived: sum of 2 quarters · filed 2013-11-08 | $40.37M 10-Q · filed 2013-11-08 | $54.58M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-06-30 | $12.78M 10-Q · filed 2013-08-08 | $28.30M 10-Q · filed 2013-08-08 | $42.51M derived: sum of 3 quarters · filed 2014-03-10 | $57.61M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-03-31 | $15.53M 10-Q · filed 2013-05-09 | $15.44M 10-Q · filed 2012-05-08 | $29.73M derived: sum of 2 quarters · filed 2014-03-10 | $44.83M derived: sum of 3 quarters · filed 2014-03-10 | $59.27M derived: sum of 4 quarters · filed 2014-03-10 | |||
| 2011-12-31 | $14.21M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $29.31M derived: sum of 2 quarters · filed 2014-03-10 | $43.75M derived: sum of 3 quarters · filed 2014-03-10 | $57.25M 10-K · filed 2014-03-10 | $56.90M 10-K · filed 2012-03-06 | |||
| 2011-09-30 | $15.10M 10-Q · filed 2012-11-08 | $14.77M 10-Q · filed 2011-11-03 | $29.54M derived: sum of 2 quarters · filed 2012-11-08 | $43.04M 10-Q · filed 2012-11-08 | $41.69M 10-Q · filed 2011-11-03 | $68.00M derived: sum of 4 quarters · filed 2013-03-11 | ||
| 2011-06-30 | $14.44M 10-Q · filed 2012-08-08 | $13.97M 10-Q · filed 2011-08-04 | $27.94M 10-Q · filed 2012-08-08 | $26.91M 10-Q · filed 2011-08-04 | $52.89M derived: sum of 3 quarters · filed 2013-03-11 | $72.09M derived: sum of 4 quarters · filed 2013-03-11 | ||
| 2011-03-31 | $13.40M 10-Q · filed 2012-05-08 | $38.45M derived: sum of 2 quarters · filed 2013-03-11 | $57.65M derived: sum of 3 quarters · filed 2013-03-11 | $72.39M derived: sum of 4 quarters · filed 2013-03-11 | ||||
| 2010-12-31 | $25.05M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $44.25M derived: sum of 2 quarters · filed 2013-03-11 | $58.98M derived: sum of 3 quarters · filed 2013-03-11 | $83.90M 10-K · filed 2013-03-11 | ||||
| 2010-09-30 | $19.20M 10-Q · filed 2011-11-03 | $33.93M derived: sum of 2 quarters · filed 2011-11-03 | $58.85M 10-Q · filed 2011-11-03 | |||||
| 2010-06-30 | $14.74M 10-Q · filed 2011-08-04 | $39.65M 10-Q · filed 2011-08-04 | ||||||
| 2009-12-31 | $73.66M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |